

# Cancer Modeling-on-a-Chip with Future Artificial Intelligence Integration

Kirsten Lee Fetah, Benjamin J. DiPardo, Eve-Mary Kongadzem, James S. Tomlinson, Adam Elzagheid, Mohammed Elmusrati, Ali Khademhosseini,\* and Nureddin Ashammakhi\*

Cancer is one of the leading causes of death worldwide, despite the large efforts to improve the understanding of cancer biology and development of treatments. The attempts to improve cancer treatment are limited by the complexity of the local milieu in which cancer cells exist. The tumor microenvironment (TME) consists of a diverse population of tumor cells and stromal cells with immune constituents, microvasculature, extracellular matrix components, and gradients of oxygen, nutrients, and growth factors. The TME is not recapitulated in traditional models used in cancer investigation, limiting the translation of preliminary findings to clinical practice. Advances in 3D cell culture, tissue engineering, and microfluidics have led to the development of “cancer-on-a-chip” platforms that expand the ability to model the TME in vitro and allow for high-throughput analysis. The advances in the development of cancer-on-a-chip platforms, implications for drug development, challenges to leveraging this technology for improved cancer treatment, and future integration with artificial intelligence for improved predictive drug screening models are discussed.

grow to 27.5 million new cancer cases, with cancer-related mortality at an estimated 16.3 million.<sup>[1]</sup> Cancer is the second leading cause of death in the United States, with ≈1.74 million new cancer cases and 600 000 cancer-related deaths in 2018 (American Cancer Society).<sup>[1,2]</sup> Despite extensive efforts by many research groups to improve the understanding of cancer biology, identify novel therapeutics, and push these advances into clinical practice, cancer remains a global burden to human healthcare and a prominent cause of death.

Malignant tumors often undergo the process of metastasis, disseminating cancer cells to distant locations in the body.<sup>[3]</sup> During metastasis, cancer cells leave the primary tumor site and travel to other regions of the body via the blood or lymphatic system, forming new tumors in other organs or tissues.<sup>[3]</sup> Metastatic

tumors drastically increase patient mortality and decrease the efficacy of clinical treatments.<sup>[4]</sup> While patients diagnosed with localized tumors can often be successfully treated with surgery and/or radiation, with relatively high survival rates, a diagnosis of metastatic cancer often designates a terminal illness, with a five-year survival rate less than 20% for half of all cancer

## 1. Introduction


Cancer is a leading cause of death worldwide, with an estimated 17.0 million new cancer cases and 9.5 million cancer-related deaths reported by the International Agency for Research on Cancer in 2018.<sup>[1]</sup> By 2040, global incidence will

K. L. Fetah, Prof. A. Khademhosseini, Prof. N. Ashammakhi  
Center for Minimally Invasive Therapeutics  
University of California  
Los Angeles, CA 90095, USA  
E-mail: khademh@ucla.edu; n.ashammakhi@ucla.edu

K. L. Fetah, Prof. A. Khademhosseini, Prof. N. Ashammakhi  
California NanoSystems Institute (CNSI)  
University of California  
570 Westwood Plaza, Los Angeles, CA 90095, USA

K. L. Fetah, Prof. A. Khademhosseini, Prof. N. Ashammakhi  
Department of Bioengineering  
University of California  
Los Angeles, CA 90095, USA

Dr. B. J. DiPardo, Dr. J. S. Tomlinson  
Department of Surgery  
David Geffen School of Medicine  
University of California  
Los Angeles, CA 90095, USA

 The ORCID identification number(s) for the author(s) of this article can be found under <https://doi.org/10.1002/sml.201901985>.

E.-M. Kongadzem, Prof. M. Elmusrati, Prof. N. Ashammakhi  
School of Technology and Innovations  
University of Vaasa  
FI-65101 Vaasa, Finland

Prof. A. Elzagheid  
Biotechnology Research Center  
Libyan Authority for Research, Science and Technology  
Tripoli, Libya

Prof. A. Khademhosseini, Prof. N. Ashammakhi  
Department of Radiological Sciences  
David Geffen School of Medicine  
University of California  
Los Angeles, CA 90095, USA

Prof. N. Ashammakhi  
Division of Plastic Surgery  
Department of Surgery  
Oulu University  
FI-90001 Oulu, Finland

DOI: 10.1002/sml.201901985

sites.<sup>[5]</sup> The development of cancer metastases often necessitates the use of chemotherapeutic drugs, which enter the body's circulation and travel, inflicting cytotoxicity on tumor cells and therefore impacting tumor growth and, ideally, curing the patient.<sup>[6]</sup>

The staggeringly high mortality and morbidity rates associated with cancer highlight the need for more efficacious therapies. Drug discovery and development for cancer treatment has been slow in its clinical translation due to a high attrition rate during drug development.<sup>[7]</sup> Despite robust research efforts, only 5.1% of anticancer drugs that enter phase I clinical trials receive Food and Drug Administration (FDA) approval.<sup>[8]</sup> One reason for this low translation rate is the poor ability of disease and drug screening models to predict patient outcomes.<sup>[7]</sup> The improved ability to more accurately and rapidly identify drug candidates and eliminate ineffective drugs as potential candidates would drastically improve the drug development process and accelerate the rate of clinical translation.<sup>[7,9]</sup>

A central challenge in translating research advances from preclinical models to patient therapies and treatments is the immense complexity of the tumor microenvironment (TME). The TME is a complex niche created by each tumor and influenced by a tumor's interactions.<sup>[10,11]</sup> It is comprised of the non-cancerous cells within a tumor that support tumor cell growth. The TME consists of a heterogeneous population of stromal and immune cells, microvasculature, extracellular matrix (ECM), and the proteins produced and secreted by tumor cells. The TME is characterized by its specific mechanical properties and complex gradients of oxygen, nutrients, and growth factors. These components influence tumor biology and play a role in invasion, metastasis, and treatment outcomes.<sup>[12]</sup> A comprehensive review of TME components' respective roles in these processes and cancer treatment can be found in previously published review papers.<sup>[10,13]</sup> Current preclinical models for anticancer drug screening fall into two categories, *in vitro* and *in vivo* models. The simplest, and most commonly used, *in vitro* model is the traditional 2D culture of immortalized cell lines.<sup>[14]</sup> 2D culture is relatively inexpensive and allows for high-throughput analysis and is therefore commonly used in studies aiming to elucidate cancer biology or identify novel chemotherapeutic agents. However, despite their advantages, these models subject cancer cells to artificially 2D growth conditions and lack key components of the TME that influence cancer biology and drug response, including the stroma, ECM, tumor mechanical properties, and intertumoral gradients.<sup>[14,15]</sup> As a result, the predictive value of these models is limited. Another traditional preclinical tool for cancer studies is *in vivo* animal models. Animal models for cancer mimic the tumor microenvironment to a greater fidelity than simplified 2D cell culture.<sup>[16–18]</sup> These models are often used to study an individual patient's tumor *ex vivo* via patient-derived xenograft (PDX) models. However, despite their advantages, these models have several limitations. While these models provide a 3D environment, a comparison between two vastly different species cannot be made with high accuracy. As a result, there is often a disparity between the outcomes of cancer related drug studies in animal models and patient trials. In addition, animal studies are often cost prohibitive. Thus, an alternative model is needed to provide efficient and effective drug screening to guide the



**Kirsten Fetah** is a graduate student in the Department of Bioengineering at UCLA. Her graduate school research is focused on biomaterials for tissue engineering and miniaturized tissue systems for personalized medicine. Previously, she worked at UC Berkeley in the field of mechanobiology, using synthetic biology techniques to control cytoskeletal contractility and study how cells sense the mechanical properties of their environment. Kirsten is interested in collaborating with clinical partners through her work at UCLA in order to translate research done in the lab into new therapeutic solutions.



**Ali Khademhosseini** is the Levi Knight Professor of Bioengineering, Chemical Engineering and Radiology at UCLA. He is the Founding Director of the Center for Minimally Invasive Therapeutics at UCLA. Previously, he was a professor of medicine at Harvard Medical School. His research interest is focused on combining micro- and nanoengineering approaches with advanced biomaterials for regenerative medicine applications.



**Nureddin Ashammakhi** is an associate director of the Center for Minimally Invasive Therapeutics at UCLA, leading translational research in regenerative therapy. He has extensive experience with biodegradable implants, drug release, and nanofiber-based scaffolds. Currently, he is working on 3D bioprinting and organ-on-a-chip models for regenerative and personalized medicine. He was previously a professor of biomaterials technology in Tampere University of Technology, Finland, Chair of Regenerative Medicine in Keele University, UK and Adjunct Professor in Oulu University, Finland before he joined University of California – Los Angeles first as a visiting professor (scholar) and then as a faculty.

initial selection of chemotherapeutic agents for cancer patients. This need drives the development of 3D models, which seek to integrate the advantages of *in vivo* and *in vitro* techniques for improved cancer studies and drug development.

Recently, much effort has been put into the development of organ-on-a-chip platforms that can recapitulate both the biology and physiology of *in vivo* human tumors.<sup>[7,19–21]</sup> The majority of these platforms are designed to mimic crucial functions of organs and tissues, enabling the investigation of pharmacokinetics and pharmacodynamics.<sup>[19]</sup> These approaches employ the use of multichannel, 3D microfluidic chips to simulate the mechanics, activity, and physiological response of organs. Cancer-on-a-chip models are at the frontier of nanomedicine and offer promising utility as sophisticated microsystems to elucidate the mechanisms of cancer biology and improve anticancer drug development. As new organ-on-a-chip platforms are developed, becoming increasingly higher throughput, large data sets are generated, bringing forth new challenges and opportunities. The development of these high-throughput organ-on-a-chip platforms gives rise to the application of deep learning-based analysis processes for high-throughput drug screening, making way for a new avenue of cutting-edge research.<sup>[22]</sup> In this review, we will highlight seminal cancer-on-a-chip papers and new advances in the field, incorporating discussion on key features of the TME and the challenges associated with recapitulating its features. We will discuss recent applications of cancer-on-a-chip models for pathomorphological and drug development studies, with special emphasis on the integration of and challenges associated with combining these platforms with machine learning (ML) and data processing technologies. Future perspectives on how cancer-on-a-chip and machine learning algorithms can synergize to improve anticancer drug development will be considered.

## 2. Anticancer Drug Development and the Need for Improved Predictive Models

The anticancer drug development process starts with the identification of effective compounds via preclinical models. These compounds are then evaluated further in sequential human clinical trials to assess safety, dosing, and efficacy, comparing the drug in question to the current standard of care. Unfortunately, the majority of compounds identified as effective in preclinical models are found to be not safe or efficacious in these later studies.<sup>[18,23]</sup> The low predictive value of preclinical models increases the cost and resources expended during the drug development process. Such clinical trial failures point to the need for improved preclinical models that mimic the TME with high fidelity.<sup>[1,18,23]</sup>

In addition to the challenges associated with current preclinical models, progress in anticancer drug development is hindered by the complexity of cancer biology. Cancer biology is highly heterogeneous and complex on several levels: among tumor subtypes, individual patients, and separate tumors within one patient. Selection of chemotherapeutic agents is currently dominated by evidence generated from randomized clinical trials (RCTs), in which patients are assigned to treatment groups by chance. Given the ongoing development of many new

chemotherapeutics and the necessity to monitor the stability of previously developed agents, it is impossible to perform RCTs to investigate all FDA-approved drugs for each tumor type, let alone trials to investigate all drug combinations. An individual patient's cancer biology is unique and tumors of the same histologic subtype often show vastly different responses to therapies. Thus, initiatives for precision, or personalized, medicine have emerged.<sup>[24]</sup> This emerging field is based on the principle that the genetic and molecular information of an individual patient can be used to deploy more effective, less toxic, and patient-specific treatments.<sup>[24]</sup> Furthermore, in order to personalize the chemotherapy regimens given to a patient and optimize the chance of an effective response, there exists the need to develop robust models to perform drug screening for both general cancer subtypes and for an individual patient's tumors.

## 3. Comparison of Preclinical Cancer Models

### 3.1. 2D Monoculture

In traditional 2D cultures, cells are grown as an adherent monolayer in a culture dish, attached to the plastic dish surface.<sup>[25,26]</sup> Assays derived from 2D monolayers are easy to use, low cost, and high throughput. However, despite their advantages, these assays are quite limited in their predictive value. One such limitation is the inability of 2D cell cultures to mimic the native structure of tissues and tumors.<sup>[14,26]</sup> The 2D culture environment does not recapitulate the cell–cell and cell–environment interactions present in native tumors.<sup>[14,26]</sup> These interactions are fundamental to cell proliferation, cell differentiation, gene and protein expression, stimuli response, drug metabolism, and other cellular functions.<sup>[14,27]</sup> Another limitation of 2D culture models is that cells in an adherent monolayer have infinite, homogenous access to key nutrients, including oxygen and metabolites.<sup>[14,26]</sup> *In vivo*, cancer cells have more variable access to nutrients and oxygen due to natural tumor architecture.<sup>[27]</sup> Because of these disadvantages, there exists the need to find alternate models which better mimic the native cancer microenvironment.

### 3.2. Transwell Model

Transwell assays are used to study the invasion and migration of cancer cells.<sup>[28]</sup> These assays use a cell culture insert made of a porous, polymeric membrane that allows for migration through the pores.<sup>[29,30]</sup> Transwell assay applications include migration, invasion, and transendothelial migration.<sup>[29,30]</sup> Migration assays, the simplest transwell-based assay, seed cancer cells on top of the polymeric membrane insert and measure the ability of the cells to translocate through the membrane's pores.<sup>[28–30]</sup> Invasion assays are more complex in that they add a layer of ECM on top of the porous membrane and characterize cancer cell migration through the ECM.<sup>[28–30]</sup> Transwell assays are used as both a tool for drug screening and a model for studying cancer cell migration, invasion, extravasation, and matrix remodeling. The transwell-based assay serves as a straightforward *in vitro* technique for studying a tumor's

ability to metastasize to a secondary site. However, despite their advantages, transwell assays study the motility of individual cells and, as a result, are not an optimal tumor model.

### 3.3. Three-Dimensional Culture Models

Three-dimensional culture models use various matrices or scaffolds for cancer cells to grow and ECM, thus mimicking important components of the TME. Scaffolds support cell attachment, growth, and morphogenesis.<sup>[29]</sup> These scaffolds are typically made from natural or synthetic materials, such as gelatin, collagen, alginate, hyaluronic acid, polyethylene glycol, or polylactide, polylactide-co-glycolide, and various other polymers.<sup>[7]</sup> These scaffold-based approaches are ideal in that they have similar mechanical and physical properties to the native ECM and TME.<sup>[7]</sup> More recently, alternative approaches to scaffolds have been developed, including the creation of cell spheroids via 3D bioprinting.<sup>[7]</sup> These structures have improved perfusion due to their vascularization but are limited by technical challenges and their capacity to recapitulate complex tissue types.<sup>[21]</sup> Various other methods have been developed, for example, the use of nonadhesive polyethylene glycol di-methacrylate hydrogel microwells to produce cancer cell multicellular aggregates,<sup>[31]</sup> hanging drop cultures, and spinner cultures. While these methods can be improved upon, these models are an important foundation for more novel platforms, such as cancer-on-a-chip, as they model tumor-tumor cell interactions, native ECM, and may be designed to recapitulate the biophysical properties of native tumor.

### 3.4. Animal Models

Preclinical animal models are a necessary component in the process of anticancer drug development and discovery.<sup>[32]</sup> These *in vivo* models capture physiological complexity with higher fidelity than 2D monoculture techniques.<sup>[7]</sup> While these models have vastly improved our understanding of cancer, they are also limited in their capacity. One such shortcoming of animal models is their limited translatability to humans. The inability of animal models to fully recapitulate human cancer physiology is evidenced by the failure in clinical trials of drugs identified in preclinical results.<sup>[7]</sup> To improve the replicative value of *in vivo* animal studies, PDX tumor models have been established. PDX models are created by implanting cancer cells or tissues derived from patient tumors into immunodeficient mice.<sup>[33]</sup> PDX models are used extensively in cancer research, as they simulate human tumor biology *in vivo*. While these models better replicate human tumor biology, the use of immunocompromised animals impedes analysis of the immune system's response to a tumor.<sup>[17,34]</sup> An additional challenge with PDX models is the establishment rate. Previous research reports a successful formation rate of implanted tumors as being 39.2%.<sup>[35]</sup> As animal models are expensive, highly regulated, and limited by a low initiation rate, there are constraints to the number of studies that can be done, preventing the PDX model from being a high-throughput assay. In addition, the procedure of creating PDX models takes months to establish,

making PDXs logistically difficult for use in making timely clinical decisions.<sup>[36]</sup> Despite their advantages, animal models do not practically allow for the high-throughput assessment of multiple combinations of chemotherapeutics, highlighting further the need for high-throughput platforms to be used in precision medicine to identify anticancer drugs on a patient-specific basis. A thorough discussion of preclinical models and their advantages and disadvantages can be found in previously published reviews.<sup>[14,26,28,37]</sup>

## 4. Cancer-on-a-Chip Platform

### 4.1. Organ-on-a-Chip Structure and Function

In recent years, organ-on-a-chip platforms have significantly advanced for several applications, such as preclinical drug screening and disease modeling. Organs-on-a-chip are micro-devices with miniaturized tissues to model human organ physiology *in vitro*.<sup>[38–41]</sup> Organ-on-a-chip devices incorporate microfluidics with 3D tissues to recapitulate native organ complexity and cues, for example, electrical signals, fluid flow, and biochemical cues. Organ-on-a-chip has many advantages, including improved recapitulation of native microenvironment, simplicity, decreased cost, and reproducibility. The microfluidic chip components are traditionally made of polydimethylsiloxane (PDMS), which has ideal properties, such as transparency, low toxicity to cells, and high permeability to O<sub>2</sub> and CO<sub>2</sub> gases.<sup>[39]</sup> Cells are cultured in small chambers within these miniature chips, either in 2D monolayers or 3D suspensions, to emulate organ tissues. Membranes may be integrated into the microfluidic chips, creating multiple channels and separating the cells.<sup>[40–47]</sup> The microfluidic components of organ-on-a-chip platforms recapitulate *in vivo* conditions, such as flow, pressure, and nutrient levels. Organs-on-a-chip are also able to expose the cells or tissues to controlled laminar flow of fluids, improving the accuracy of biomarker identification and drug screening.<sup>[48]</sup> Examples of organ-on-a-chip platforms include thrombosis-on-a-chip,<sup>[49]</sup> alveolus-on-a-chip,<sup>[50]</sup> lung-on-a-chip,<sup>[45]</sup> and gut-on-a-chip.<sup>[45]</sup> More details of organ-on-a-chip development and applications can be found in previously published reviews.<sup>[38,51,52]</sup>

### 4.2. Organ-on-a-Chip Advantages

Organ-on-a-chip platforms are miniaturized, reducing the required sample sizes and materials consumed during *in vitro* testing.<sup>[53]</sup> As a result, organ-on-a-chip testing is less costly than alternative preclinical models, such as animals. In addition, organs-on-a-chip perhaps offer an ethical advantage and alternative to animal models. Due to the miniaturized nature of these platforms, it has become possible to use materials from a single animal to run hundreds of tests, instead of running a single test on hundreds of animals. The small size and low cost of organs-on-a-chip allow for accelerated research and testing, as many samples can be run on one device. Another advantage of organs-on-a-chip is the ability to recapitulate native microenvironments, modeling mechanical stresses, nutrient diffusion,

and fluid flow, for example. These advantages have sparked interest in combining organ-on-a-chip platforms with other 3D models, such as organoid cultures. While 3D organoids may recapitulate a singular organ, organ-on-chip platforms mimic how these organs interact with their in vitro environment. Further discussion on the combination of 3D organoid cultures with organs-on-a-chip can be found in recent reviews.<sup>[53,54]</sup>

### 4.3. Cancer-on-a-Chip Platforms

Cancer-on-a-chip platforms were developed by using cancer and tumor-derived cells and matrix materials inside of previously developed cancer-on-a-chip platforms. The microfluidic devices developed for organ-on-a-chip platforms have been shown to be promising for applications in large-scale, high-throughput anti-cancer drug screening, study of metastatic cancer processes, and screening of drugs against a patient's individual tumor (personalized medicine).<sup>[7,13,21,55]</sup> In the subsequent sections, we will focus our discussion on cancer-on-a-chip models that recapitulate components of the TME. A discussion of cancer-on-a-chip to evaluate nanomedicine<sup>[19]</sup> and for personalized medicine applications<sup>[56]</sup> can be found in recently published reviews.

## 5. Applications of Cancer-on-a-Chip Technologies

The development of cancer-on-a-chip systems has greatly expanded the ability of in vitro models to recapitulate the TME. With the recent development of dynamic culture systems and the advent of organ-on-a-chip platforms, which offer spatially and temporally controlled microenvironments, the improved cancer modeling has become an attractive prospect for studying both cancer biology and treatment options.<sup>[57]</sup> Although

this field is still in its infantile stage, its progress is expected to grow exponentially. Cancer-on-a-chip models offer many advantages. First, they allow researchers to mimic elements of the TME in isolation or in concert, including the addition of cancer cells to stromal cells, immune constituents, vasculature, and oxygen, nutrient, or growth factor gradients. Cancer-on-a-chip systems also allow for noninvasive real-time monitoring of crucial cellular parameters and recapitulate the complex cellular and extracellular microenvironment of tumors. These abilities allow for the investigation into the role microenvironmental features play in the progressing stages of cancer metastasis.<sup>[24]</sup>


Cancer-on-a-chip models have been used to evaluate aspects of cancer biology in several different malignancies, examining local tumor invasion, metastasis and angiogenesis, as well as serving as models for immunotherapy research and drug screening.<sup>[4,7,29]</sup> These studies examined several types of cancer as model systems, including some of the most common and deadly cancers, for example, breast,<sup>[36,58,59]</sup> lung,<sup>[20,60]</sup> and pancreatic cancer.<sup>[15]</sup> It is very important to work on these frontiers, but, nevertheless, other cancer models should be developed both to address special characteristics and the subtypes of cancers, as well as the comprehensive spectrum of cancers, including those of the head and neck. A summary of the cancer-on-a-chip studies discussed in the manuscript can be found in **Table 1**.

### 5.1. Cancer-on-a-Chip Systems Model Tumor Morphology and Drug Response with High Fidelity

Cancer-on-a-chip systems that recapitulate in vivo cancers and tumors are fundamental to improved strategies for anti-cancer drug selection. In 2014, Vidi et al. developed a cancer-on-a-chip model, mimicking cancer mammary ducts.<sup>[61]</sup> The

**Table 1.** Summary of cancer-on-a-chip studies.

No.	Cancer type	Method	Result	Authors	Year	Ref.
1.	Breast cancer	Microfluidic 3D in vitro model for breast cancer metastasis to bone	3D in vitro data on extravasation and micrometastasis generation of breast cancer cells within bone microenvironment	Bersini et al.	2014	[59]
2.	Breast cancer	3D bone-on-a-chip for bone metastasis study of breast cancer cells	Unique hallmarks of breast cancer bone colonization observed, previously only seen in vivo	Hao et al.	2018	[58]
3.	Breast cancer	Disease-on-a-chip model in which cancer grows within phenotypically normal breast luminal epithelium on semicircular acrylic supports	Mimicry of tumor environment provides a framework for the design and test of anticancer therapies.	Vidi et al.	2014	[61]
4.	Breast cancer	3D high-throughput microfluidic platform for screening of three triple negative breast cancer lines against several anticancer drugs	High-throughput organ-on-a-chip platform to select therapies in personalized medicine	Lanz et al.	2017	[36]
5.	Cancer immune interactions	Organ-on-chip tool to evaluate cancer-immune cell interactions	Quantitative confirmation of the essential role of FPR1 in cancer chemotherapy response	Biselli et al.	2017	[66]
6.	Lung cancer	Multiorgan microfluidic chip mimicking in vivo micro-environment of lung cancer metastasis	Multiorgan system provides useful tool to investigate cell-cell interactions in metastasis.	Xu et al.	2016	[20]
7.	Lung	Organ-on-a-chip model recapitulates orthotopic lung cancer growth and therapeutic response.	Discovery of mechanical stimuli dependent TKI therapy resistance	Hassell et al.	2017	[60]
8.	Pancreatic ductal adeno-carcinoma	Microfluidic 3D platform for culturing pancreatic ductal adenocarcinoma cells	Growth characteristics closer to those of cells grown as spheroids than as classical 2D in vitro cultures	Beer et al.	2017	[15]



**Figure 1.** Photographs and simulation of the HepaChip. A) Image of the chip, with eight culture chambers, fluid inlet and outlet, and gold electrodes. B) Enlarged view of single chamber, with two electrodes and three assembly ridges. C) Simulation of the flow and cell trajectory inside of the culture chamber. D) Live/dead staining of BxPC3, growing on the assembly ridge. E) Live/dead staining of PANC1, spread on well channel walls and bottom. F) Mitosis of MxPC3, observed after 16 h culture. Reproduced under the terms of the Creative Commons Attribution 4.0 International License.<sup>[15]</sup> Copyright 2017, The Author(s). Published by Springer Nature.

breast-on-a-chip device was comprised of a breast luminal epithelium monolayer on a semicircular acrylic support. Tumor cells grown in these channels were different morphologically than the same cells cultured on a traditional flat surface. Additionally, tumor nodules cultured in these channels displayed a different anticancer drug sensitivity compared to their flat and monoculture counterparts, providing new insight for the design and testing of cancer therapies.


An important component of developing a new platform is the comparison of its results to the existing standard. In 2017, Beer et al. compared their pancreatic ductal adenocarcinoma-on-a-chip model to other *in vitro* and to *in vivo* PDX models (Figure 1).<sup>[15]</sup> Their HepaChip consisted of eight chambers, each containing three 1 mm × 60 μm cell culture regions, which were coated with collagen. These cell culture regions were irradiated by UV light, creating acid groups to which collagen was bound. Electrodes were integrated on the wall of each chamber, creating dielectrophoretic forces. Pancreatic ductal adenocarcinoma (PDAC) human cell lines were cultured inside of the polymer chambers. The combination of microfluidics and dielectrophoresis assembled *in vitro* micro-organs. The experimental results show morphological and growth characteristics more like that of spheroid cultures than the 2D culture. Compared to traditional 2D preclinical platforms, the HepaChip model is better at capturing cell–cell and cell–ECM interactions, and thus it is more biomimetic, representing a more predictive model with potential to be useful in the development of personalized pancreatic cancer treatment.

Another more recent study by Lanz et al. utilized breast cancer cell lines for developing a high-throughput breast-cancer-on-a-chip to study the response of triple negative breast cancer cell lines (MDA-MB-453, MDA-MB-231, AND HC1937) to anticancer therapeutic drugs (paxlitaxel, olaparib, and cisplatin).<sup>[36]</sup> Several conditions were

evaluated, including cell seeding density, ECM composition, biomechanical conditions, and the response to therapy, as compared to those seen in 2D cultures.<sup>[36]</sup> Differences in drug response were observed in different ECM materials (Matrigel vs BME2rgf vs collagen 1). This microfluidic platform allowed for the simultaneous culture of 96 perfused microtissues (≈10 cells per data point). Additional advantages include the use of small quantities of material and the ability to perform drug screening using patient-derived samples. This strategy is a vast improvement from previous 3D culture techniques, as it allows for constant perfusion of the culture medium. While the tested system did not entirely capture *in vivo* complexities, this strategy presents a more high-throughput and efficient system for testing and raises the possibility for use in developing personalized medicine by determining appropriate drug sensitivity and predicting individual patient response in a real-time fashion.

## 5.2. Cancer-on-Chip Systems Model Mechanical Properties of the Tumor Microenvironment

In addition to modeling tumor morphology and drug response, cancer-on-a-chip platforms also offer improved modeling of the TME's mechanical properties, such as its stiffness, which plays a role in cancer progression.<sup>[62]</sup> In 2017, Hassell et al. studied non-small-cell lung cancer (NSCLC) in an organ-on-a-chip device (Figure 2).<sup>[60]</sup> This NSCLC-on-a-chip model recapitulated organ microenvironment-specific growth, tumor dormancy, and response to tyrosine kinase inhibitor (TKI), a therapy used *in vivo* in human patients. This new platform revealed a newly observed mechanical sensitivity of NSCLCs. TKI therapeutic response was discovered to be sensitive to the physical cues of breathing motions, with mechanical breathing motions



**Figure 2.** Human orthotopic lung cancer-on-a-chip model. A) Schematic of a cross section through the designed microfluidic chip. B) Microscopy image of a cross section of the two central channels of the alveolus chip taken via fluorescence microscopy. C) Immunofluorescence microscopy image of a cluster of GFP labeled NSCLC cells, implanted in the airway chip. D) Quantification of NSCLC densities after implantation in the chip. E) Growth pattern of GFP labeled lung cancer cells within the epithelial monolayer. F) Lung cancer cell growth dynamics. Reproduced with permission.<sup>[60]</sup> Copyright 2017, Elsevier.

perhaps suppressing NSCLC response to TKI therapy. This new finding elucidates understanding of NSCLC and can help to explain therapy resistance in patients with lung tissue that remains aerated and mobile, as mechanical strain leads to the downregulation of epidermal growth factor receptor (EGFR), which is partly responsible for decreased response to therapy in persistent tumors.<sup>[60]</sup> The understanding of this previously unstudied mechanism has implications in future mitigation of drug resistance and development of efficacious therapies.

These findings further validate the need for the development of dynamic systems and platforms, which take into consideration the components of the TME.<sup>[63]</sup> Future work need not only consider traditional properties, such as cell type and ECM, but also dynamic properties, such as mechanical stiffness, to mimic in vivo events and develop more reliable predictive models.


### 5.3. Cancer-on-Chip Systems Model Tumor Immune Microenvironment

Immune system elements play a large role in the TME, with crosstalk between the immune and cellular TME components.<sup>[64]</sup> Interactions within the TME contribute to cancer initiation (carcinogenesis), progression, and metastasis. After a tumor escapes immune recognition, the TME affects

immune cell behavior and the two play a synergistic role in tumor progression.<sup>[65]</sup> Organ-on-a-chip platforms can be useful in the development of immuno-oncology models. Such a model was shown by Biselli et al. in their work on mononuclear and cancer cells (Figure 3).<sup>[66]</sup> The presented cancer-on-chip model studied the crosstalk between immune cells, leukocytes, and human breast cancer cells treated with chemotherapeutics.<sup>[76]</sup> The study compared leukocytes with and without the FRP1 gene and concluded that leukocytes lacking the FPR1 gene do not recognize the chemotherapy-treated cells, while leukocytes with expression of FPR1 perform random walks, drifting toward the tumor cells and establishing persistent interactions with them.<sup>[66]</sup> These findings demonstrate the capacity and necessity to develop immune-oncology methods using the organ-on-a-chip platform, as immune response is a key component of the in vivo environment (evidenced by the cell-cell interactions of immune and tumor cells).<sup>[66,67]</sup> A detailed discussion on crosstalk between the TME and immune system can be found in a recent review paper.<sup>[64]</sup>

### 5.4. Cancer-on-Chip Systems Model Tumor Angiogenesis, Microvasculature, and Lymphatics

Angiogenesis plays a critical role in both the growth and metastatic spread of tumor cells.<sup>[68,69]</sup> The TME can regulate



**Figure 3.** A) General schematic of the immune-oncology chip, whose design features six reservoirs for cell loading and culture medium replacement and four compartments for cell culture. B) Detailed view of the four chambers. C) Picture of the whole device. D–F) Trajectories of FPR1 CC cells, FPR1 CA cells, and FPR1 AA cells, respectively. Reproduced under the terms of the Creative Commons Attribution 4.0 International License.<sup>[66]</sup> Copyright 2017, The Author(s). Published by Springer Nature.

angiogenesis, via ECM molecules and growth factors within the TME.<sup>[70]</sup> Increased vascularity has been observed, even in the bone marrow, in patients with hematological malignancies.<sup>[68]</sup> Despite this observation, the role of angiogenesis in regulating hematological malignancies is not well understood.<sup>[68]</sup> In 2016, Zheng et al. used a 3D microfluidic angiogenesis-on-a-chip to study the unique morphogenic signatures of angiogenesis induced by leukemic cells, with or without bone marrow stromal cell coculture.<sup>[68]</sup> The microfluidic device was fabricated from PDMS by soft lithography, forming three parallel microchannels, separated by trapezoidal posts. The central channel was filled with collagen type I and the side channels with endothelial and leukemia derived cells. The role of leukemic cells on angiogenic induction and vessel formation was observed. This model has not yet been achieved via existing 2D culture techniques. Angiogenesis in the bone marrow is a highly dynamic process and is critically dependent on both cell–cell and cell–matrix interactions, which are abundant in the native bone marrow microenvironment, presenting the critical need for functional angiogenic assays.

The lymphatic system serves as a method through which many cancers can disseminate. New microfluidic flow systems make it possible to study the role of lymphatic capillary microenvironment in the lymphatic invasion of mammary adenocarcinoma cells.<sup>[69]</sup> This platform allows for the quantification of cell transmigration and its dynamics, revealing that both luminal and transluminal flow are important in increasing tumor transmigration, as opposed to the previous belief that this behavior was a result of luminal flow alone. This study provides new insights on flow-mediated regulation of lymphatic tumor migration and presents a new tool for exploration

of cancer therapy, allowing for medium-to-high throughput studies.

### 5.5. Cancer-on-Chip Systems Model Cancer Invasion and Metastasis

Cancer metastases contribute to over 90% of cancer-related mortalities.<sup>[71]</sup> Thus, the use of experimental models to effectively represent the metastatic microenvironment is warranted. Metastasis-on-a-chip platforms allow for the study of important aspects of the metastasis process, such as physicochemical factors from the tumor stroma and heterocellular interactions, which influence cell migration, as well as physicochemical gradients, which lead to tumor cell motility and invasion.<sup>[21]</sup> An early study to visualize metastatic progression in 2007 by Yates et al. developed a system to visualize the interactions between tumor cells and target organs to which they metastasize.<sup>[72]</sup> This study investigated hepatic cells with prostate and breast carcinoma cells, examining tumor cell invasion and expansion. They found that tumor cells were unable to grow without a supporting hepatic microtissue, due to the absence of paracrine functionality or liver structure support. The developed system served as a crucial model for examining tumor–host interactions during the processes of metastasis and invasion, circumventing the limitations of previous models.

More recently, microfluidic metastasis-on-a-chip models have been designed to more accurately study cancer progression.<sup>[59]</sup> These studies investigate the various stages of cancer metastasis, lymphangiogenesis,<sup>[73]</sup> and angiogenesis, intravasation,<sup>[74,75]</sup> arrest, organ-specific extravasation,<sup>[76–79]</sup> and the



formation of micro-metastases. Additionally, studies looked at invasion rate as a method for studying cancer.<sup>[80]</sup> In 2018, Hao et al. developed a bone-on-a-chip model to aid in the study of breast cancer metastasis to bone tissue.<sup>[58]</sup> This new bone-on-a-chip design is miniaturized, increasing experimental throughput, and facilitates easy and frequent observations. Fundamental markers of breast cancer colonization of the bone were observed and confirmed with *in vivo* collected data.

Another organ-on-a-chip study constructed a multiorgan microfluidic chip platform to investigate lung cancer metastasis.<sup>[20]</sup> This multi-organ-on-a-chip system consisted of four organs, one upstream lung and three downstream organs, with three parallel microchannels formed by PDMS. Bronchial epithelial, lung cancer, microvascular endothelia, and fibroblast cells were grown in the lung organ, and astrocytes, osteocytes, and hepatocytes were grown in the three downstream organs, mimicking the metastasis of lung cancer to the brain, bone, and liver. Damage to the astrocytes, osteocytes, and hepatocytes validated metastasis in the organs-on-a-chip system.

Migration and invasion studies in cancer-on-a-chip models improved upon more traditional assays, such as transwell cultures and scratch-wound assays. Recent work from Toh et al. utilized a microfluidic cancer-on-chip cell migration model which resolved different aspects of cell intravasation (the invasion of cancer cells into a blood or lymphatic vessel) in a biologically relevant 3D microenvironment.<sup>[81]</sup> The described platform incorporates a 3D microenvironment, which plays a critical role in the invasive properties of cancer cells, with a microfluidic system, creating an appealing model for the testing of antimigration and anti-invasion cancer drugs, which can be multiplexed to allow for high-throughput assays. The development of new tumor models will be crucial in improving management of cancers and the prognosis of cancer patients and, as a result, may help ultimately in the reduction of health-care costs.<sup>[82]</sup>

### 5.6. Cancer-on-Chip Systems for Use in Chemotaxis Studies

The cell types and factors in the TME influence the occurrence of cancer migration modes.<sup>[83]</sup> Microfluidic organ-on-a-chip systems have been used to study the chemotaxis, or migration due to chemical gradients, of cancer cells.<sup>[84]</sup> Aung et al. developed a cancer-on-a-chip platform with cancer spheroids encapsulated in gelatin methacryloyl (GelMA) hydrogel, surrounded by an endothelial cell barrier.<sup>[84]</sup> For this study, investigators harnessed the chemoattracted-induced motility of human umbilical vein endothelial cells (HUVEC) and cancer spheroids to control organization within the microfluidic device. Cancer cell migration was observed in relation to the presence and location of the chemotactic source. Although this study uses an endothelial cell–cancer cell coculture, this approach provides a framework for establishing platforms with the same level of complexity as physiological tumors. These models bridge the gap between *in vitro* cell culture and *in vivo* animal experiments and serve as a promising platform for studying tumor behaviors in the vascular system.<sup>[85]</sup> More complex,

hybrid cancer-on-a-chip models incorporate 3D tumor tissue models, such as spheroids, resulting in more advanced and high-performance models.<sup>[86,87]</sup> In the future, these models will have elucidated mechanisms for cancer invasion, such as chemotaxis, and present the possibility of developing migration inhibitory drugs.<sup>[84]</sup>


### 5.7. Cancer-on-a-Chip Platform for Cancer Treatment and Drug Development

Improved 3D culture models have been developed with the prospect of accelerating the selection of therapies by improving the ability to predict anticancer drug responses.<sup>[36]</sup> One avenue of new cancer-on-a-chip studies involves the use of 3D microfluidic devices for improved anticancer drug screening and selection. Examples of these new strategies include a 3D high-throughput perfused microfluidic platform for testing new breast cancer therapies, developed by Lanz et al. (Figure 4),<sup>[36]</sup> and microfluidic platform for studying biomolecular characteristics of pancreatic ductal adenocarcinoma cells, developed by Beer et al.<sup>[15]</sup> These strategies employ microfluidic-based devices, which show promise to be used for personalized pharmacological testing. Microfluidic systems can be employed for the fabrication of drug delivery systems having precisely controlled size and shape, rigidity, as well as drug-loading. In addition, microfluidic systems can be efficiently used for the evaluation of drug-releasing preparations.<sup>[88]</sup> Because organ-on-a-chip platforms can recapitulate human physiology and pathophysiology, they can be effectively helpful in translating new therapeutics to the clinic including advanced nanomedicine.<sup>[19]</sup>

Hassell et al. found that microenvironmental cues elicited by cells, as well as mechanical cues, significantly influence non-small-cell lung cancer growth *in vitro*.<sup>[60]</sup> More importantly, their data demonstrate the ability of orthotopic cancer chip models to mimic growth patterns observed *in vivo* in patients and is consistent with that of human clinical trials, a feature which had not previously been recapitulated *in vitro*.<sup>[60]</sup> Other strategies to mimic the TME include the use of multicellular aggregates (“microtumors”) of subtype-specific breast cancer cells, by Singh et al.,<sup>[31]</sup> human-on-chip microvascular assay for visualization of tumor cell extravasation dynamics, by Chen et al.,<sup>[76]</sup> as well as development of an array of gut-on-a-chips for drug development.<sup>[89]</sup> The ultimate value in these new developments lies in their potential to allow for high-throughput drug screening of chemotherapeutics on *ex vivo* models of individual patients’ tumors.

## 6. High-Throughput Cancer-on-a-Chip Studies for Large Data Generation

Cancer-on-a-chip models are advantageous for preclinical drug screening, as they can be designed to allow for high-throughput analysis of antitumor drug response and other biological parameters.<sup>[19,90]</sup> In order to generate the large quantities of data needed to appropriately predict drug efficacy and potential side effects, as seen in clinical trials, high-throughput systems need



**Figure 4.** Microtiter cancer-on-a-chip plate for anticancer breast cancer drug testing. A) Photo of the OrganoPlate platform. B–D) Closeup, top, and side view of an individual channel, respectively. E) Photo demonstrating the filling of an ECM channel. F) Epifluorescence microscopy images showing morphology and viability of MDA-MB-453 in Matrigel, BME2rgf, and collagen I, under both static and perfusion conditions. G) Quantification of the effect of ECM composition, seeding density, and perfusion or static conditions on cell viability. Reproduced under the terms of the Creative Commons Attribution 4.0 International License.<sup>[36]</sup> Copyright 2017, The Author(s). Published by Springer Nature.


to be developed. With the use of cancer-on-a-chip platforms, this type of large data creation and large-scale analysis is possible.

### 6.1. Large Data Generating Cancer-on-a-Chip Studies

In order to perform high-throughput studies, a large number of devices must be fabricated with high fidelity, reproducibility, and homogeneity or a device must have the capacity to run many tests on a single chip. In 2017, Chen et al. published a protocol extension describing the fabrication of a microfluidic device for modeling early metastasis in *Nature Protocols*.<sup>[76]</sup> Their device was made from PDMS and featured three

hydrogel regions, separated by channels for media. Microposts marked the device between each region. The central region was filled with a fibrin gel and HUVEC suspension and the two peripheral regions were filled with a fibrin gel and human lung fibroblast suspension. Their device served as a model for microcirculation, representing transendothelial migration and early metastasis. They reported the capacity to fabricate and seed up to 36 devices at a time without impacting cell viability. Coupled with rapid quantification, their large number of devices per experiment is expected to allow for high parametric and throughput study, generating a large quantity of data.<sup>[86]</sup>

To address the challenges associated with current *in vitro* and *in vivo* preclinical models, such as the need for large



**Figure 5.** A) Photograph of the bottom of an OrganoPlate, showing 40 microfluidic channel networks and the top of a 384 well plate device. B) Zoomed in photograph of a single microfluidic channel network, with three channels joining in the center. C, D) Horizontal and vertical cross section. E) 3D sketch of the chip, comprised of a tubule, an extracellular matrix gel, and a perfusion lane. Reproduced under the terms of the Creative Commons Attribution 4.0 International License.<sup>[89]</sup> Copyright 2017, The Author(s). Published by Springer Nature.

numbers of cell or animal materials, researchers have developed microdevices with up to thousands of microwells, allowing for high-throughput testing. In 2014, Zhang et al. developed a microfluidic device with 4000 ultraminiaturized wells for high-throughput monitoring of chemotactic migration and invasion.<sup>[91]</sup> Their multiwell invasion (MI) chip was fabricated from PDMS using photolithography. The MI chip was comprised of four compartments, each containing 10, 10 × 10 microwell arrays, equaling 4000 microwells. They fabricated both round (200 μm diameter) and square (200 × 200 μm) wells, with a depth of 160 μm. The MI chips were used to perform 3D cell invasion assays with breast cancer cell lines, to validate the chip's capacity to be used as a model for studying metastatic breast cancer. The MI chip used a small cell sample size (less than 1000 cells), allowing it to be used in the future with limited cell sources, such as primary tumor cell samples. The chip can be used in the future to run many tests at one time or run tests on rare samples, making it a useful future tool for clinicians to evaluate the behavior of cancer cells and anticancer drug regimens.

Another method for generating large data sets via organ-on-a-chip is the fabrication of multiple models on a single device. To our knowledge, there is not currently published literature joining multiple cancer-on-a-chip platforms. However, groups have multiplexed organ-on-a-chip devices together for other applications. Work in the organ-on-a-chip field reports the use of an array of gut-on-a-chip devices joined together, comprising a total of 357 gut tubes.<sup>[89]</sup> The OrganoPlate (shown in **Figure 5**) is a 384-well plate platform housing 40 networks of microfluidic channels. Each OrganoPlate housed 40 epithelial gut tubes, which were tested against drug compounds at

different concentrations to study the effect on epithelial barrier integrity. The study generated over 20 000 data points, making it the largest reported organ-on-chip data set thus far. This study's high-throughput nature shows the promise of organ-on-a-chip platforms for use as new, efficient, and reliable preclinical models, with applications in anticancer drug testing.<sup>[63,89,92]</sup>

## 6.2. Large Data Management and Extraction of Information

With high-throughput platforms, such as organ-on-a-chip, generating unprecedented quantities of data, there lies the need for appropriate data management and analysis systems. While cancer-on-a-chip platforms have been rapidly developing, machine learning algorithms to manage these data have been developing in parallel. New data management strategies should incorporate four core pillars. The first pillar in data management is the hardware implementation of microchips, with appropriate sensors and microsystems to measure the desired parameters. The second pillar of large data management is data collections, transmission, and storage. The third pillar required is advanced machine learning algorithms to extract information from the available huge data sets. Finally, the fourth pillar concerns the interpretation of obtained data and its applications in the discovery of new theories.

Cancer-on-a-chip platform sensors continuously measure attributes of all cells within the device. The data flow can be of extremely high volume; for example, if there are 50 000 cells under investigation, each with 20 measured factors min<sup>-1</sup>, then one would receive ≈2 GB of data each day (variable by the coding method of the collected data). With several parallel platforms

and prolonged data collection (potentially months of collection), the size of the collected data may be exceedingly large.

After data collection, the next large stage is the big data processing. For this purpose, we rely on highly sophisticated ML algorithms, which can be divided into two categories: supervised or unsupervised learning.<sup>[93]</sup> These algorithms take into consideration the number of cells ( $N$ ), number of parameters or attributes ( $M$ ), and the number of samples ( $T$ ). In this example, we can define health status as  $H$  and assign binary values of 0 (dead cell) and 1 (fully healthy cell). After collecting big size data, we can build some model (dynamic or otherwise) for the relationship between cellular attributes and health. The data are typically divided into two parts, with one part (the learning portion) used for modeling and the second used for validation; the first part should be large enough in size to capture important mapping relations between the attributes and the output status  $H$ . Other alternative ML algorithms to be used include recurrent type networks with deep learning structure. There are many ML algorithms with different concepts and criteria. A crucial component to any model, however, is keeping the complexity enough to obtain a good generalized model but avoid creating unnecessary complexity, which may give high errors in the validation and testing phase.

There are other alternative approaches to supervised learning which are not discussed in this review. More information regarding ML algorithms can be found in other sources.<sup>[93]</sup> Another challenge of big data processing is the interpretation of the ML algorithm results. Advanced artificial intelligence (AI) algorithms may be used to help human experts interpret ML outcomes. The discussed methodologies will aid in the processing and interpretation of data collected from future high-throughput, large data generating studies. With real-time data collection and processing, in the future, researchers will be able to perform trials on millions of therapeutic agents against a patient's specific tumor. Microfluidics, sensors, computing facilities, smart algorithms, and intelligent microautomated systems can be joined as the basis of advanced systems for next-generation anticancer drug design and development.<sup>[57,94]</sup>

## 7. Challenges and Future Work

Recent studies involving cancer-on-a-chip technologies have made great strides in better recapitulating the TME and in vivo cancer microenvironment. However, there is still work to be done identifying the fundamental TME elements needed to better mimic cancer tissue, for both the study of cancer biology and improved predictive ability of preclinical models for anticancer drug development. The development of personalized cancer-on-a-chip platforms for patients' primary tumor tissues will be a large step forward in harnessing the capabilities of cancer-on-a-chip platforms. This advancement will result in precision medicine and personalized oncology. Incorporation of TME elements, such as oxygen concentration and cytokine concentration gradients, will increase the complexity of cancer-on-a-chip models, improving the predictive power of these platforms. Once developed, there will likely be many challenges in the adoption of these technologies, that is, standardization and validation against current models.

With the adoption of organ-on-a-chip technologies, future oncology treatment is expected to be vastly different than today's regimens. As we move toward personalized oncology models, one predicted outcome is the use of patient-derived cells and extracted ECMs in chip technologies, capturing the biochemical, biophysical, and mechanical cues of the in vivo human cancer microenvironment. Another advantage of cancer-on-a-chip technologies is the capability for high-throughput, personalized screening of anticancer drug treatment and therapies. The capabilities of these platforms may also be expanded and used for more innovative cancer detection,<sup>[51]</sup> for example, on-chip blood tests to replace bone biopsies for multiple myeloma.<sup>[81]</sup>

## 8. Conclusions

Once cancer-on-a-chip technologies are fully realized, the current regimented practice of choosing specific chemotherapeutics based solely on tumor type will seem imprecise and inaccurate. Personalized cancer chemotherapy will eventually be adopted and the use of cancer-on-a-chip models will become the clinical standard, allowing for more precise and individual function-based selection of chemotherapeutics. After the predictive power of these models are demonstrated, on-a-chip tests will serve a central role in the development and approval of new cancer therapeutics, replacing current pre-clinical models. Adoption of these new technologies will both accelerate and decrease the costs of the drug development process and increase the precision of cancer therapy, benefiting patients, physicians, and care providers, as well as pharmaceutical and insurance companies.

## Acknowledgements

The authors acknowledge funding from the National Institutes of Health (AR057837, AR066193, EB021857-01A1, HL137193-01, EB024403-01-01, CA214411-01A1, EB023052-01A1, HL140618-01, GM126831, HL140951, AR073135, and AR069564), Department of Defense: BiofabUSA Quick Start Project, and American Heart Association Transformational Project Award (18TPA34230036).

## Conflict of Interest

The authors declare no conflict of interest.

## Keywords

artificial intelligence, cancer models, chemotherapy, microfluidics, organ-on-a-chip

Received: April 20, 2019

Revised: July 22, 2019

Published online: November 13, 2019

[1] *Global Cancer Facts & Figures*, 4th ed., American Cancer Society, Atlanta, GA 2018.

[2] R. L. Siegel, K. D. Miller, A. Jemal, *Ca-Cancer J. Clin.* **2018**, 68, 7.

- [3] *NCI Dictionary of Cancer Terms*, National Institute of Health, Bethesda, MD **2019**.
- [4] Y.-H. V. Ma, K. Middleton, L. You, Y. Sun, *Microsyst. Nanoeng.* **2018**, 4, 17104.
- [5] P. S. Steeg, *Nat. Rev. Cancer* **2016**, 16, 201.
- [6] D. S. Shewach, R. D. Kuchta, *Chem. Rev.* **2009**, 109, 2859.
- [7] S. J. Hachey, C. C. W. Hughes, *Lab Chip* **2018**, 18, 2893.
- [8] K. Smietana, M. Siatkowski, M. Moller, *Nat. Rev. Drug Discovery* **2016**, 15, 379.
- [9] I. Kola, J. Landis, *Nat. Rev. Drug Discovery* **2004**, 3, 711.
- [10] T. L. Whiteside, *Oncogene* **2008**, 27, 5904.
- [11] M. Wang, J. Zhao, L. Zhang, F. Wei, Y. Lian, Y. Wu, Z. Gong, S. Zhang, J. Zhou, K. Cao, X. Li, W. Xiong, G. Li, Z. Zeng, C. Guo, *J. Cancer* **2017**, 8, 761.
- [12] M. A. Swartz, N. Iida, E. W. Roberts, S. Sangaletti, M. H. Wong, F. E. Yull, L. M. Coussens, Y. A. DeClerck, *Cancer Res.* **2012**, 72, 2473.
- [13] Z. Wang, R. Samanipour, K. Kim, in *Biomedical Engineering: Frontier Research and Converging Technologies* (Eds: H. Jo, H.-W. Jun, J. Shin, S. Lee), Springer International Publishing, Cham, Switzerland **2016**, pp. 209–233.
- [14] M. Kapałczyńska, T. Kolenda, W. Przybyła, M. Zajączkowska, A. Teresiak, V. Filas, M. Ibbs, R. Bliźniak, Ł. Łuczewski, K. Lamperska, *Arch. Med. Sci.* **2018**, 14, 910.
- [15] M. Beer, N. Kuppala, M. Stefanini, H. Becker, I. Schulz, S. Manoli, J. Schuette, C. Schmees, A. Casazza, M. Stelzle, A. Arcangeli, *Sci. Rep.* **2017**, 7, 1325.
- [16] R. Chakrabarti, Y. Kang, *Methods Mol. Biol.* **2015**, 1267, 367.
- [17] M. Cekanova, K. Rathore, *Drug Des., Dev. Ther.* **2014**, 8, 1911.
- [18] C.-P. Day, G. Merlino, T. Van Dyke, *Cell* **2015**, 163, 39.
- [19] Y. S. Zhang, Y. N. Zhang, W. Zhang, *Drug Discovery Today* **2017**, 22, 1392.
- [20] Z. Xu, E. Li, Z. Guo, R. Yu, H. Hao, Y. Xu, Z. Sun, X. Li, J. Lyu, Q. Wang, *ACS Appl. Mater. Interfaces* **2016**, 8, 25840.
- [21] R. Portillo-Lara, N. Annabi, *Lab Chip* **2016**, 16, 4063.
- [22] G. Urban, K. M. Bache, D. Phan, A. Sobrino, A. K. Shmakov, S. J. Hachey, C. Hughes, P. Baldi, *IEEE/ACM Trans. Comput. Biol. Bioinf.* **2018**, 16, 1029.
- [23] M. Dhandapani, A. Goldman, *J. Mol. Biomark. Diagn.* **2017**, 8, 356.
- [24] J. W. Gray, G. B. Mills, *Cancer Discovery* **2015**, 5, 1130.
- [25] S. Breslin, L. O'Driscoll, *Drug Discovery Today* **2013**, 18, 240.
- [26] K. Duval, H. Grover, L.-H. Han, Y. Mou, A. F. Pegoraro, J. Fredberg, Z. Chen, *Physiology* **2017**, 32, 266.
- [27] F. Pampaloni, E. G. Reynaud, E. H. Stelzer, *Nat. Rev. Mol. Cell Biol.* **2007**, 8, 839.
- [28] M. E. Katt, A. L. Placone, A. D. Wong, Z. S. Xu, P. C. Searson, *Front. Bioeng. Biotechnol.* **2016**, 4, 12.
- [29] H.-F. Tsai, A. Trubelja, A. Q. Shen, G. Bao, **2017**, 14, 20170137.
- [30] C. R. Justus, N. Leffler, M. Ruiz-Echevarria, L. V. Yang, *J. Visualized Exp.* **2014**, 51046.
- [31] M. Singh, S. Mukundan, M. Jaramillo, S. Oesterreich, S. Sant, *Cancer Res.* **2016**, 76, 3732.
- [32] B. A. Ruggeri, F. Camp, S. Miknyoczki, *Biochem. Pharmacol.* **2014**, 87, 150.
- [33] Y. Lai, X. Wei, S. Lin, L. Qin, L. Cheng, P. Li, *J. Hematol. Oncol.* **2017**, 10, 106.
- [34] M. R. Carvalho, D. Lima, R. L. Reis, V. M. Corrello, J. M. Oliveira, *Trends Biotechnol.* **2015**, 33, 667.
- [35] M. Moro, G. Bertolini, R. Caserini, C. Borzi, M. Boeri, A. Fabbri, G. Leone, P. Gasparini, C. Galeone, G. Pelosi, L. Roz, G. Sozzi, U. Pastorino, *Sci. Rep.* **2017**, 7, 6689.
- [36] H. L. Lanz, A. Saleh, B. Kramer, J. Cairns, C. P. Ng, J. Yu, S. J. Trietsch, T. Hankemeier, J. Joore, P. Vulto, R. Weinshilboum, L. Wang, *BMC Cancer* **2017**, 17, 709.
- [37] L. C. Kimlin, G. Casagrande, V. M. Virador, *Mol. Carcinog.* **2013**, 52, 167.
- [38] K. Ronaldson-Bouchard, G. Vunjak-Novakovic, *Cell Stem Cell* **2018**, 22, 310.
- [39] G. M. Whitesides, *Nature* **2006**, 442, 368.
- [40] A. K. Achyuta, A. J. Conway, R. B. Crouse, E. C. Bannister, R. N. Lee, C. P. Katnik, A. A. Behensky, J. Cuevas, S. S. Sundaram, *Lab Chip* **2013**, 13, 542.
- [41] J. A. Brown, V. Pensabene, D. A. Markov, V. Allwardt, M. D. Neely, M. Shi, C. M. Britt, O. S. Hoilet, Q. Yang, B. M. Brewer, P. C. Samson, L. J. McCawley, J. M. May, D. J. Webb, D. Li, A. B. Bowman, R. S. Reiserer, J. P. Wikswo, *Biomicrofluidics* **2015**, 9, 054124.
- [42] S. Musah, A. Mammoto, T. C. Ferrante, S. S. F. Jeanty, M. Hirano-Kobayashi, T. Mammoto, K. Roberts, S. Chung, R. Novak, M. Ingram, T. Fatanat-Didar, S. Koshy, J. C. Weaver, G. M. Church, D. E. Ingber, *Nat. Biomed. Eng.* **2017**, 1, 0069.
- [43] K. J. Jang, A. P. Mehr, G. A. Hamilton, L. A. McPartlin, S. Chung, K. Y. Suh, D. E. Ingber, *Integr. Biol.* **2013**, 5, 1119.
- [44] H. J. Kim, D. E. Ingber, *Integr. Biol.* **2013**, 5, 1130.
- [45] H. J. Kim, D. Huh, G. Hamilton, D. E. Ingber, *Lab Chip* **2012**, 12, 2165.
- [46] D. Huh, B. D. Matthews, A. Mammoto, M. Montoya-Zavala, H. Y. Hsin, D. E. Ingber, *Science* **2010**, 328, 1662.
- [47] R. Booth, H. Kim, *Lab Chip* **2012**, 12, 1784.
- [48] F. Zheng, F. Fu, Y. Cheng, C. Wang, Y. Zhao, Z. Gu, *Small* **2016**, 12, 2253.
- [49] Y. S. Zhang, F. Davoudi, P. Walch, A. Manbachi, X. Luo, V. Dell'Erba, A. K. Miri, H. Albadawi, A. Arneri, X. Li, X. Wang, M. R. Dokmeci, A. Khademhosseini, R. Oklu, *Lab Chip* **2016**, 16, 4097.
- [50] A. Jain, R. Barrile, A. D. van der Meer, A. Mammoto, T. Mammoto, K. De Ceunynck, O. Aisiku, M. A. Otieno, C. S. Louden, G. A. Hamilton, R. Flaumenhaft, D. E. Ingber, *Clin. Pharmacol. Ther.* **2018**, 103, 332.
- [51] G. Kaushik, J. Leijten, A. Khademhosseini, *Stem Cells* **2017**, 35, 51.
- [52] B. Zhang, A. Korolj, B. F. L. Lai, M. Radisic, *Nat. Rev. Mater.* **2018**, 3, 257.
- [53] K. Fetah, P. Tebon, M. J. Goudie, J. Eichenbaum, L. Ren, N. Barros, R. Nasiri, S. Ahadian, N. Ashammakhi, M. R. Dokmeci, A. Khademhosseini, *Prog. Biomed. Eng.* **2019**, 1, 012001.
- [54] T. Takebe, B. Zhang, M. Radisic, *Cell Stem Cell* **2017**, 21, 297.
- [55] J. J. F. Sleeboom, H. E. Amirabadi, P. Nair, C. M. Sahlgren, J. M. J. den Toonder, *Dis. Models Mech.* **2018**, 11, dmm033100.
- [56] A. Sontheimer-Phelps, B. A. Hassell, D. E. Ingber, *Nat. Rev. Cancer* **2019**, 19, 65.
- [57] M. Elmusrati, N. Ashammakhi, *J. Craniofac. Surg.* **2018**, 29, 1682.
- [58] S. Hao, L. Ha, G. Cheng, Y. Wan, Y. Xia, D. M. Sosnoski, A. M. Mastro, S. Y. Zheng, *Small* **2018**, 14, 1702787.
- [59] S. Bersini, J. S. Jeon, G. Dubini, C. Arrigoni, S. Chung, J. L. Charest, M. Moretti, R. D. Kamm, *Biomaterials* **2014**, 35, 2454.
- [60] B. A. Hassell, G. Goyal, E. Lee, A. Sontheimer-Phelps, O. Levy, C. S. Chen, D. E. Ingber, *Cell Rep.* **2017**, 21, 508.
- [61] P. A. Vidi, T. Maleki, M. Ochoa, L. Wang, S. M. Clark, J. F. Leary, S. A. Lelievre, *Lab Chip* **2014**, 14, 172.
- [62] B. Emon, J. Bauer, Y. Jain, B. Jung, T. Saif, *Comput. Struct. Biotechnol. J.* **2018**, 16, 279.
- [63] J. Ahn, Y. J. Sei, N. L. Jeon, Y. Kim, *Bioengineering* **2017**, 4, 64.
- [64] P. Parente, P. Parcesepe, C. Covelli, N. Olivieri, A. Remo, M. Pancione, T. P. Latiano, P. Graziano, E. Maiello, G. Giordano, *Gastroenterol. Res. Pract.* **2018**, 2018, 7530619.
- [65] S. Upadhyay, N. Sharma, K. B. Gupta, M. Dhiman, *J. Cell. Biochem.* **2018**, 119, 5028.
- [66] E. Biselli, E. Agliari, A. Barra, F. R. Bertani, A. Gerardino, A. De Ninno, A. Mencattini, D. Di Giuseppe, F. Mattei, G. Schiavoni,

- V. Lucarini, E. Vacchelli, G. Kroemer, C. Di Natale, E. Martinelli, L. Businaro, *Sci. Rep.* **2017**, *7*, 12737.
- [67] E. Agliari, E. Biselli, A. De Ninno, G. Schiavoni, L. Gabriele, A. Gerardino, F. Mattei, A. Barra, L. Businaro, *Sci. Rep.* **2015**, *4*, 6639.
- [68] Y. Zheng, Y. Sun, X. Yu, Y. Shao, P. Zhang, G. Dai, J. Fu, *Adv. Healthcare Mater.* **2016**, *5*, 1014.
- [69] M. Pisano, V. Triacca, K. A. Barbee, M. A. Swartz, *Integr. Biol.* **2015**, *7*, 525.
- [70] K. Mittal, J. Ebos, B. Rini, *Semin. Oncol.* **2014**, *41*, 235.
- [71] C. L. Chaffer, R. A. Weinberg, *Science* **2011**, *331*, 1559.
- [72] C. Yates, C. R. Shepard, G. Papworth, A. Dash, D. B. Stolz, S. Tannenbaum, L. Griffith, A. Wells, *Adv. Cancer Res.* **2007**, *97*, 225.
- [73] S. Kim, M. Chung, N. L. Jeon, *Biomaterials* **2016**, *78*, 115.
- [74] H. Lee, W. Park, H. Ryu, N. L. Jeon, *Biomicrofluidics* **2014**, *8*, 054102.
- [75] I. K. Zervantonakis, S. K. Hughes-Alford, J. L. Charest, J. S. Condeelis, F. B. Gertler, R. D. Kamm, *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 13515.
- [76] M. B. Chen, J. A. Whisler, J. Frose, C. Yu, Y. Shin, R. D. Kamm, *Nat. Protoc.* **2017**, *12*, 865.
- [77] J. S. Jeon, S. Bersini, M. Gilardi, G. Dubini, J. L. Charest, M. Moretti, R. D. Kamm, *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 214.
- [78] Q. Zhang, T. Liu, J. Qin, *Lab Chip* **2012**, *12*, 2837.
- [79] J. S. Jeon, I. K. Zervantonakis, S. Chung, R. D. Kamm, J. L. Charest, *PLoS One* **2013**, *8*, e56910.
- [80] K. F. Lei, H. P. Tseng, C. Y. Lee, N. M. Tsang, *Sci. Rep.* **2016**, *6*, 25557.
- [81] Y.-C. Toh, A. Raja, H. Yu, D. van Noort, *Bioengineering* **2018**, *5*, 29.
- [82] D. Caballero, S. Kaushik, V. M. Correló, J. M. Oliveira, R. L. Reis, S. C. Kundu, *Biomaterials* **2017**, *149*, 98.
- [83] E. T. Roussos, J. S. Condeelis, A. Patsialou, *Nat. Rev. Cancer* **2011**, *11*, 573.
- [84] A. Aung, J. Theprungsirikul, H. L. Lim, S. Varghese, *Lab Chip* **2016**, *16*, 1886.
- [85] R. Huang, W. Zheng, W. Liu, W. Zhang, Y. Long, X. Jiang, *Sci. Rep.* **2015**, *5*, 17768.
- [86] S. Sart, R. F. X. Tomasi, G. Amselem, C. N. Baroud, *Nat. Commun.* **2017**, *8*, 469.
- [87] Y. Choi, E. Hyun, J. Seo, C. Blundell, H. C. Kim, E. Lee, S. H. Lee, A. Moon, W. K. Moon, D. Huh, *Lab Chip* **2015**, *15*, 3350.
- [88] H. Zhang, Y. Zhu, Y. Shen, *Small* **2018**, *14*, 1800360.
- [89] S. J. Trietsch, E. Naumovska, D. Kurek, M. C. Setyawati, M. K. Vormann, K. J. Wilschut, H. L. Lanz, A. Nicolas, C. P. Ng, J. Joore, S. Kustermann, A. Roth, T. Hankemeier, A. Moisan, P. Vulto, *Nat. Commun.* **2017**, *8*, 262.
- [90] N. Kashaninejad, M. R. Nikmaneshi, H. Moghadas, A. K. Oskouei, M. Rismanian, M. Barisam, M. S. Saidi, B. Firoozabadi, *Micromachines* **2016**, *7*, 130.
- [91] Y. Zhang, L. Zhou, L. Qin, *J. Am. Chem. Soc.* **2014**, *136*, 15257.
- [92] N. Ashammakhi, M. Elmusrati, *bioRxiv* **2018**, 273847.
- [93] E. Alpaydin, *Introduction to Machine Learning*, The MIT Press, Cambridge, MA **2016**.
- [94] E. Kongadzem, *Parallel Faculty of Technology and Innovations*, University of Vassa, Vassa, Finland **2018**.